Looking Forward by Glancing Back: A Review of the Current Biopharma Deals Landscape with Emerging Trends in Licensing and M&A
Speaker: Laura Vitez, Principal Business Analyst, Thomson Reuters
Date/Time: Friday, May 29th, 8:00-10:00 AM, presentation begins at 8:30 sharp
Place: Novartis Pharmaceuticals Corporation 201 Industrial Road
(2nd floor lobby, Navier-Stokes conference rooms)
San Carlos, CA 94070
(Admission is free, but registration is required by 10:00 AM 5/27)
Laura Vitez is the Principal Business Analyst for Thomson Reuters working with life science firms to identify and execute an optimized business development strategy. Since 2003 she has been serving as a consultant to the senior teams of top-tier small and mid-sized biotech companies in the San Francisco and San Diego areas.
Laura has participated in alliances generating more than $2 billion in value for her clients and companies. These include the acquisitions of Intellikine by Takeda/Millennium, and of Rinat by Pfizer; profit sharing agreements including Intellikine with Infinity/Purdue, KaloBios with Sanofi-Pasteur, and Rinat with Genentech; and multiple other arrangements including Maxygen with Codexis, Signature with MDS Sciex, Schwarz with Aryx, and various licenses and partnerships for Cell Genesys.
Prior to launching her consulting practice Laura led the early business development efforts of Signature Biosciences, a technology firm developing microwave spectroscopy-based instrumentation; ran west coast business development operations for Schwarz Pharma, a mid-size German pharmaceutical company; held a managing director role at the merchant banking arm of Burrill & Company; and was the twelfth employee at Cell Genesys, working on business development of their cell and gene therapy programs.
Laura began her career at the bench, working in labs at Somatogen Inc., National Jewish Center for Immunology and Respiratory Medicine, Northwestern University, and Indiana University. She holds a BA in mathematics and chemistry and an MS in Biochemistry, Molecular and Cellular Biology, and completed a business series at University of California at Berkeley.
Recent trends in life sciences deal-making based on Thomson Reuters Recap data will be presented. In addition, a detailed analysis of emerging trends in licensing and M&A over the last 12 months will be provided, including:
-Key financial metrics
-Most active dealmakers
-Trends by therapeutic area
-A showcase of the largest deals signed in 2014
Register early, you won't want to miss this!